CSCO Guideline Preview | Professor Xinan Sheng Interprets the Core Advantages and Key Updates of the 2026 CSCO Renal Cancer Guidelines

CSCO Guideline Preview | Professor Xinan Sheng Interprets the Core Advantages and Key Updates of the 2026 CSCO Renal Cancer Guidelines

The Chinese Society of Clinical Oncology (CSCO) Renal Cancer Guidelines have become one of the most influential and widely adopted clinical references in the field of kidney cancer in China. Built upon evidence-based medicine while remaining highly practical for everyday clinical use, the guidelines continue to evolve alongside rapid advances in renal cancer therapeutics.
J Pathology | Prof. Guoliang Yang and Prof. Xianbin Su Reveal the Molecular Landscape and Cellular Origins of Bladder Squamous Cell Carcinoma

J Pathology | Prof. Guoliang Yang and Prof. Xianbin Su Reveal the Molecular Landscape and Cellular Origins of Bladder Squamous Cell Carcinoma

Squamous cell carcinoma (SCC) of the bladder is a rare but highly aggressive malignancy associated with poor clinical outcomes and limited responsiveness to conventional therapies. Recently, Professor Guoliang Yang’s team from Renji Hospital, Shanghai Jiao Tong University School of Medicine, together with Professor Xianbin Su’s group from the Institute of Systems Biomedicine at Shanghai Jiao Tong University, published a landmark study in the Journal of Pathology titled “Cellular origins and etiological factors for squamous cell carcinoma and related cancer types of the bladder.”
CSCO Guideline Preview | Professor Hao Zeng Interprets the 2026 CSCO Prostate Cancer Guidelines: Advancing Precision Oncology for Chinese Patients

CSCO Guideline Preview | Professor Hao Zeng Interprets the 2026 CSCO Prostate Cancer Guidelines: Advancing Precision Oncology for Chinese Patients

As one of the most common malignancies affecting men worldwide, prostate cancer requires continuously evolving diagnostic and therapeutic strategies. With rapid advances in precision medicine and the growing body of high-quality clinical evidence generated from Chinese patient populations, the 2026 CSCO Guidelines for Prostate Cancer introduce major updates aimed at better addressing the biological characteristics and clinical needs of patients in China.
AOT 2026 | Professor Xiaodong Mo: Clinical Positioning and Key Decision-Making Considerations for Allogeneic Hematopoietic Stem Cell Transplantation in Non-Hodgkin Lymphoma

AOT 2026 | Professor Xiaodong Mo: Clinical Positioning and Key Decision-Making Considerations for Allogeneic Hematopoietic Stem Cell Transplantation in Non-Hodgkin Lymphoma

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading hematology experts from around the world to discuss cutting-edge innovations and future directions in hematopoietic stem cell transplantation.
ZUCCS’16 | A Global Invitation to Advance Colorectal Cancer Care

ZUCCS’16 | A Global Invitation to Advance Colorectal Cancer Care

Globally, colorectal cancer is the third most commonly diagnosed malignancy and the second leading cause of cancer-related death, placing a substantial burden on public health worldwide. Owing to its large population base, China accounts for 28.76% of global colorectal cancer incidence and 30.60% of related deaths, making it a major driving force in advancing colorectal cancer prevention and treatment worldwide. In recent years, breakthroughs in innovative drug development, novel surgical techniques, and robotic-assisted surgery in China have significantly advanced the global standard of colorectal cancer care.
CURC & ARUF | Professor Tao Xu: New Perspectives on Endocrine Therapy for mHSPC — Evidence Review and Clinical Practice Centered on Enzalutamide

CURC & ARUF | Professor Tao Xu: New Perspectives on Endocrine Therapy for mHSPC — Evidence Review and Clinical Practice Centered on Enzalutamide

Prostate cancer is one of the most common malignant tumors of the male genitourinary system in China. Among these patients, metastatic hormone-sensitive prostate cancer (mHSPC) carries a particularly poor prognosis and remains a major clinical challenge. In recent years, novel hormonal therapies (NHTs), represented by enzalutamide, have continuously reshaped the treatment landscape of mHSPC. With the release of long-term follow-up data from landmark studies such as ARCHES and ENZAMET, the combination of enzalutamide plus androgen deprivation therapy (ADT) has demonstrated durable survival benefits across a broad range of subgroups, including high- and low-volume disease, synchronous and metachronous metastases, and patients treated before or after chemotherapy.
4th Clinical Research Conference on Urologic Oncology | Breaking Through the Post-PD-1 Era: Professor Xieqiao Yan Interprets the Latest Advances in Kidney Cancer Research from ASCO GU 2026

4th Clinical Research Conference on Urologic Oncology | Breaking Through the Post-PD-1 Era: Professor Xieqiao Yan Interprets the Latest Advances in Kidney Cancer Research from ASCO GU 2026

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Professor Xieqiao Yan from Peking University Cancer Hospital delivered a comprehensive presentation on the latest advances in kidney cancer therapy. His report focused on emerging clinical evidence surrounding the HIF-2α inhibitor belzutifan, particularly its evolving role in advanced clear cell renal cell carcinoma (ccRCC) after PD-1–based therapy, as well as in the postoperative adjuvant setting. The findings offer important new insights for clinical decision-making in the post-PD-1 era.